Nov. 27 Company Quick Takes: Orexo, GAIA in second deal for substance abuse digital therapy; plus PDUFA date for Verrica's skin infection candidate and $25M fol
Orexo gets U.S. rights to GAIA's alcohol abuse digital therapeutic
Orexo AB (SSE:ORX) licensed exclusive U.S. rights from GAIA AG to vorvida, a digital therapeutic to treat alcohol use disorder; financial terms are undisclosed. Orexo will be responsible for FDA approval and commercialization of vorvida. The deal follows an August partnership between the two companies to develop a psychosocial support product intended to enhance the use of Orexo's Zubsolv buprenorphine/naloxone to treat opioid use disorder (see "Orexo, GAIA to Develop Digital Therapeutic for Opioid Use Disorder").
Verrica's VP-102 under FDA review
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) said FDA accepted for review an NDA for VP-102 to treat the viral skin infection molluscum contagiosum, for which there are no FDA-approved therapies. The topical formulation of cantharidin has a PDUFA date of July 13...